Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2022-06-26 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
REMAP-CAP COVID-19 Study Analysis Update 2 pages 255.7KB
Regulatory Filings
2022-06-26 English
New Clinical Trial for DMX-200 in Diabetic Kidney Disease 4 pages 284.6KB
Regulatory Filings
2022-06-06 English
Dimerix to Present at BIO International Convention 43 pages 8.1MB
Regulatory Filings
2022-06-05 English
Phase 3 FSGS Kidney Trial First Patient Recruited 4 pages 361.2KB
Regulatory Filings
2022-05-30 English
Release of Shares from Voluntary Escrow 1 page 160.
Regulatory Filings
2022-05-17 English
Dimerix presentation at Bioshares Biotech Summit 23 pages 4.4MB
Regulatory Filings
2022-05-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.